Sie befinden sind hier: Startseite > Börse > Unternehmensnachrichten > Hansa Biopharma AB Sweden

Imlifidase, Guillain-Barr&eacute;

Hansa Biopharma AB Sweden

07.08.2025 - 18:06:14

Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome

View original content:https://www.prnewswire.co.uk/news-releases/imlifidase-demonstrated-positive-safety-tolerability-and-early-efficacy-outcomes-in-15-hmedides-09-phase-2-trial-in-guillain-barre-syndrome-gbs-302008430.html

@ prnewswire.co.uk